King, Acura pain drug granted priority review

Acura Pharmaceuticals and King Pharmaceuticals have received FDA priority review status for the abuse-resistant pain drug Acurox. An expert panel previously rejected it after raising questions about the drug's anti-abuse properties. The companies have since reformulated the drug without niacin, which was originally included to cause flushing if too many pills were ingested. In the FDA's letter to King, the agency "requested additional information relating to the drug's potential misuse," notes Reuters. The PDUFA date has been set for June 17. Acura release | Report